Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00328094 · ClinicalTrials.gov registry record · NA
Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 242
- Enrollment target
NCT00328094: Clinical Trial NA study, sponsored by Beth Israel Deaconess Medical Center.
NCT00328094 is a NA study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 242 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00328094, a NA study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 242 participants
- Enrollment target
Study Summary
Aggressive intraoperative and postoperative management of blood glucose may substantially decrease perioperative cardiovascular and infectious complications in diabetic and non-diabetic patients undergoing vascular surgery. The purpose of this study is to compare the tight versus traditional blood glucose control in diabetics and non-diabetics undergoing vascular surgery in regard to their postoperative fatal and nonfatal cardiac outcomes, and the secondary effects such as rate of infections, overall morbidity and 30-day mortality.
Interventions
- DRUG continuous intravenous insulin infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2006-03 |
| Est. Completion | 2009-05 |
| Phase | NA |
Why NCT00328094 stopped before completion
NCT00328094 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which continuous intravenous insulin infusion is the first listed.
NCT00328094 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00328094 about?
NCT00328094 is a clinical study titled "Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery". Aggressive intraoperative and postoperative management of blood glucose may substantially decrease perioperative cardiovascular and infectious complications in diabetic and non-diabetic patients undergoing vascular surgery. The purpose of this study is to compare the tight versus traditional blood ...
What is the current status of trial NCT00328094?
This trial is currently terminated. It is a NA study. The enrollment target is 242 participants. The study started on 2006-03. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00328094?
The interventions under investigation include: continuous intravenous insulin infusion (DRUG).
Who is sponsoring clinical trial NCT00328094?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00328094's enrollment target sits among peer trials
242 439th of 2000 higher than 1,561 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia